Stay updated with breaking news from Src Homology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
InnoCare Pharma announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare?s novel SHP2 allosteric inhibitor, ICP-189, with ArriVent?s...
InnoCare Pharma announced the approval of the Investigational New Drug to conduct the clinical trial of ICP-189, a novel SHP2 allosteric inhibitor, in combination with furmonertinib, a highly...
Companies will collaborate on investigating a novel SHP2 inhibitor in combination with furmonertinib, a highly brain-penetrant, broadly active...
InvoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies.
Press release content from Business Wire. The AP news staff was not involved in its creation.